NCT02858492 - Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2016

Primary Completion Date

October 22, 2018

Study Completion Date

October 22, 2018

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

GSK2982772 60 mg

GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.

DRUG

Placebo

Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.

Trial Locations (16)

10117

GSK Investigational Site, Berlin

15006

GSK Investigational Site, A Coruña

24768

GSK Investigational Site, Rendsburg

29004

GSK Investigational Site, Málaga

37134

GSK Investigational Site, Verona

150030

GSK Investigational Site, Yaroslavl

432063

GSK Investigational Site, Ulyanovsk

00168

GSK Investigational Site, Rome

15-879

GSK Investigational Site, Bialystok

82-300

GSK Investigational Site, Elblag

31-513

GSK Investigational Site, Krakow

21-040

GSK Investigational Site, Świdnik

04-305

GSK Investigational Site, Warsaw

08036

GSK Investigational Site, Barcelona

SO16 6YD

GSK Investigational Site, Southampton

W12 0NN

GSK Investigational Site, London